# South America Keytruda Market

> South America Keytruda Market Research Report By Cancer Type (Melanoma, Lung cancer, Hodgkin lymphoma, Stomach cancer, Urothelial carcinoma) and By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.2%
- **2024:** $ 1,354.35 Million
- **2025:** $ 1,478.95 Million
- **2035:** $ 3,566.65 Million
- **Key Players:** Merck & Co (US), Bristol-Myers Squibb (US), Roche Holding AG (CH), AstraZeneca PLC (GB), Novartis AG (CH), Pfizer Inc (US), Eli Lilly and Company (US), Amgen Inc (US)

**Report ID:** MRFR/HC/43647-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-keytruda-market-45327

---

## Market Summary

## **South America Keytruda Market Overview**

As per MRFR analysis, the South America Keytruda Market Size was estimated at 2.48 (USD Billion) in 2024The South America Keytruda Market Industry is expected to grow from 2.71(USD Billion) in 2025 to 7.13 (USD Billion) by 2035. The South America Keytruda Market CAGR (growth rate) is expected to be around 9.2% during the forecast period (2025 - 2035).

**Key South America Keytruda Market Trends Highlighted**

The South America Keytruda market is witnessing significant trends driven by the rise in cancer prevalence and the increasing investments in healthcare infrastructure. The growing awareness among the population regarding advanced cancer therapies has led to a higher demand for immunotherapy options, such as Keytruda. Public and private healthcare sectors are prioritizing the availability of innovative treatments, making it essential for pharmaceutical companies to focus on effective distribution channels in the region. 

Opportunities in the South America Keytruda market are being captured through partnerships with local healthcare providers and government initiatives that promote access to cutting-edge cancer treatment.The alignment with national health strategies and policies has become increasingly vital for expanding the accessibility of Keytruda to a broader patient population. Moreover, collaboration with research institutions can lead to enhanced clinical trials tailored to local demographics, representing another opportunity for growth. In recent times, there has been a notable increase in advocacy for patient access to quality cancer care across South America. 

This trend is fostering a more supportive environment for the introduction and adoption of Keytruda, as various stakeholders aim to improve treatment outcomes for patients. Additionally, the integration of digital health solutions is transforming how patients receive care, paving the way for personalized treatment plans that include Keytruda.As healthcare systems evolve, the focus on patient-centered approaches continues to shape the market landscape in South America.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South America Keytruda Market Drivers**

Increasing Incidence of Cancer

The rising incidence of cancer in South America is a significant driver for the South America Keytruda Market Industry. According to regional health statistics, cancer cases in South America have increased by approximately 10% over the last five years, with reports indicating over 1.5 million new cancer cases diagnosed annually.

Organizations such as the Latin American and Caribbean Society of Medical Oncology (SLACOM) and the Pan American Health Organization (PAHO) have emphasized the urgent need for innovative treatments to combat this growing health crisis.The increasing patient population creates a robust demand for effective immunotherapies like Keytruda, propelling market growth as healthcare authorities prioritize funding and resources for cancer treatment initiatives. With escalating cases, the South America Keytruda Market Industry is positioned to expand significantly, addressing the unmet healthcare needs in the region.

Adoption of Advanced Healthcare Technologies

The adoption of advanced healthcare technologies is increasingly facilitating the delivery of Keytruda in South America. As countries in the region enhance their healthcare infrastructure, the integration of digital health solutions and telemedicine is becoming prevalent. Reports from the Brazilian Ministry of Health highlight an increase in telemedicine consultations by 75% post-pandemic, fortifying healthcare accessibility. This trend enables oncologists to recommend and monitor Keytruda treatments effectively, contributing to better patient outcomes.The South America Keytruda Market Industry is thus poised for growth as technology-driven healthcare reforms align with advancements in cancer treatment protocols.

Supportive Regulatory Environment

A supportive regulatory environment is significantly contributing to the growth of the South America Keytruda Market Industry. Various governments in South America are actively streamlining drug approval processes to expedite access to lifesaving medications. For instance, regulatory bodies such as Brazil's National Health Surveillance Agency (ANVISA) have recently reduced the approval times for oncological therapies by up to 30%.

This proactive approach not only fosters innovation but also enhances the availability of Keytruda to healthcare providers and patients.As these regulations improve, they create a favorable climate for pharmaceutical companies, thereby promoting a robust growth trajectory for the South America Keytruda Market Industry.

**South America Keytruda Market Segment Insights**

**Keytruda Market Cancer Type Insights**

The South America Keytruda Market focuses significantly on the Cancer Type segment, which plays a crucial role in its overall framework. Known for its efficacy against various types of cancers, Keytruda, a PD-1 inhibitor, has made substantial contributions in treating various malignancies. Among the prominent types, melanoma has garnered considerable attention due to its increasing incidence rates in South America. The growing awareness about skin cancer and advancements in diagnostic techniques further enhance its treatment landscape.

Similarly, lung cancer presents a critical concern, as it remains one of the leading causes of cancer-related mortality in the region, with health authorities emphasizing the need for improved therapeutic options.

Hodgkin lymphoma, known for its high cure rates, is also a focus area, reflecting the growing adaptability of treatment strategies in alignment with changing patterns of disease incidence. Stomach cancer, prevalent in several South American countries, notably exhibits unique epidemiological traits influenced by dietary factors, thus pushing for targeted treatment protocols that may incorporate Keytruda as a viable option.

Moreover, urothelial carcinoma represents a significant segment of the Keytruda Market, owing to rising awareness and early detection contributing to better patient outcomes.The South America Keytruda Market segmentation by Cancer Type clearly indicates the diverse landscape of oncology in the region as it adapts to the unique healthcare challenges and patient needs present in South America. 

Understanding these dynamics is essential for stakeholders aiming to navigate this evolving industry and leverage the opportunities arising from advancements in immunotherapy. Each cancer type analyzed reflects not only the extent of the healthcare burden but also highlights the potential avenues for innovation in treatment, creating pathways for improved patient care and health outcomes in the region.With the South America Keytruda Market growing in importance, these cancer types are likely to remain central to ongoing research and development efforts, thereby influencing future healthcare strategies across the continent.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Keytruda Market Distribution Channel Insights**

The Distribution Channel segment of the South America Keytruda Market plays a crucial role in ensuring the effective delivery of this important medication to patients in need. Within this segment, Hospital Pharmacies serve as a dominant channel, given their direct access to patients requiring immediate and specialized care. They are crucial in managing the medication processes within healthcare institutions, allowing for prompt administration and monitoring of Keytruda therapies. Specialty Pharmacies also hold significant importance as they focus on high-cost, complex medications that require specific handling and patient education.

The rise in chronic diseases within South America drives the demand for tailored medication solutions, thus benefiting both Hospital and Specialty Pharmacies. Furthermore, as the healthcare infrastructure in South America continues to improve, the capacity for these distribution channels to provide comprehensive patient management and adherence programs also expands, ensuring a better patient experience. The South America Keytruda Market segmentation reflects an increasing emphasis on these channels to optimize healthcare delivery and improve access to life-saving treatments.

**South America Keytruda Market Key Players and Competitive Insights**

The South America Keytruda Market is characterized by dynamic competition, as various pharmaceutical companies strive to capture a share of this lucrative segment focused on immunotherapy for advanced cancers. Keytruda, an innovative drug developed to harness the body's immune system against tumors, has gained significant traction in the region due to its efficacy and the increasing prevalence of cancer. The market landscape is shaped by factors including the regulatory environment, pricing strategies, distribution channels, and collaborations between companies and healthcare institutions.

These competitive insights reveal crucial aspects of how firms strategize to enhance their market presence and address the specific healthcare needs in South America

.AbbVie has established itself as a prominent player in the South America Keytruda Market through its robust emphasis on innovation and research. The company possesses a strong portfolio of products and has focused on enhancing its capabilities in immunotherapy, demonstrating a commitment to expanding treatment options for cancer patients in the region. AbbVie's strengths lie in its strong R&D investments, allowing for the consistent introduction of advanced therapeutic solutions that cater to local demographics. Furthermore, the brand’s established relationships with healthcare providers and institutions in South America have bolstered its market presence.

The company also benefits from a deep understanding of regional regulatory requirements and health policies, which enhances its ability to bring products to market efficiently and foster patient access and adherence.

Regeneron Pharmaceuticals is focused on optimizing its positioning within the South America Keytruda Market by leveraging its innovative pipeline and strategic collaborations. Known for its groundbreaking work in various therapeutic areas, the company has made significant strides in developing therapies that complement immunotherapeutic approaches like Keytruda. Its key products include a range of monoclonal antibodies and other biologics with applications in oncology. Regeneron’s strengths within the South America market include a commitment to scientific excellence and a proactive approach to engaging with local health authorities. 

The company actively pursues partnerships and potential mergers to enhance its reach and capabilities within the region, ensuring a competitive advantage in an evolving marketplace. By maintaining a focus on patient-centered solutions and expanding its therapeutic footprint, Regeneron Pharmaceuticals is well-poised to capture growth opportunities in South America’s evolving landscape for cancer treatment.

**Key Companies in the South America Keytruda Market Include**

**South America Keytruda Market Industry Developments**

In recent developments, the South America Keytruda market has seen significant growth and interest from major pharmaceutical companies. Specifically, AbbVie and Bristol-Myers Squibb have been increasing their presence in the region, with AbbVie's acquisition of Allergan in May 2020 bolstering their oncology portfolio, which includes immunotherapies that compete with Keytruda. Merck & Co continues to lead the market, driven by the increasing adoption of Keytruda in various cancer treatments.

AstraZeneca has also been active, expanding its cancer pipeline with potential combinations that include immunotherapy options. In terms of recent market valuation growth, Merck & Co reported an increase in sales in the Latin America region, benefitting from rising healthcare expenditure and greater accessibility. Over the past few years, key events include the expansion of Keytruda’s indications in breast cancer treatment in Brazil in July 2021, further solidifying its presence in oncology. The consistent investments in healthcare infrastructure across South America, alongside rising cancer incidence rates, indicate a robust environment for Keytruda and its competitors moving forward.

**South America Keytruda Market Segmentation Insights**

**Keytruda Market****Cancer Type****Outlook**

**Keytruda Market****Distribution Channel****Outlook**

## Market Drivers

### Regulatory Advancements

Regulatory advancements in South America are playing a pivotal role in shaping the keytruda market. Authorities are increasingly streamlining the approval processes for new cancer therapies, including keytruda, which may lead to faster market entry. Recent initiatives by regulatory bodies in countries like Chile and Colombia aim to enhance the efficiency of drug approval timelines. This regulatory support is crucial for pharmaceutical companies, as it allows them to bring innovative treatments to patients more swiftly. Consequently, the keytruda market is expected to experience growth as regulatory frameworks become more conducive to the introduction of advanced cancer therapies.

### Rising Patient Advocacy

Rising patient advocacy in South America is significantly influencing the keytruda market. Patient organizations and advocacy groups are becoming more vocal about the need for access to effective cancer treatments, including immunotherapies like keytruda. These groups often engage in awareness campaigns, lobbying for better healthcare policies and funding for cancer research. As patients become more informed about their treatment options, the demand for keytruda is likely to increase. This growing advocacy not only empowers patients but also encourages healthcare systems to prioritize innovative therapies, thereby driving the expansion of the keytruda market.

### Collaborations and Partnerships

Collaborations and partnerships among pharmaceutical companies, research institutions, and healthcare providers are emerging as a significant driver in the keytruda market. These alliances often focus on clinical trials, research initiatives, and educational programs aimed at improving cancer treatment outcomes. For example, partnerships between local hospitals and international pharmaceutical firms can facilitate the introduction of keytruda into new markets. Such collaborations may also enhance the understanding of immunotherapy among healthcare professionals, thereby increasing its adoption. The synergy created through these partnerships is likely to foster innovation and accelerate the growth of the keytruda market in South America.

### Growing Demand for Immunotherapy

The keytruda market in South America is experiencing a notable increase in demand for immunotherapy treatments. This shift is largely driven by the rising prevalence of various cancers, which has led to a greater emphasis on innovative therapies. According to recent data, the incidence of cancer in South America is projected to rise by approximately 20% over the next decade. As healthcare providers and patients seek more effective treatment options, the adoption of immunotherapy, particularly keytruda, is likely to expand. This trend indicates a significant opportunity for pharmaceutical companies operating in the keytruda market, as they can cater to the growing need for advanced cancer therapies.

### Investment in Healthcare Infrastructure

Investment in healthcare infrastructure across South America is a critical driver for the keytruda market. Governments and private entities are increasingly allocating funds to enhance healthcare facilities, improve access to treatments, and expand oncology services. For instance, Brazil and Argentina have initiated programs to upgrade hospitals and clinics, which may facilitate the distribution and administration of keytruda. Enhanced infrastructure not only improves patient access to innovative therapies but also supports the overall growth of the pharmaceutical sector. As a result, the keytruda market is likely to benefit from these investments, leading to increased availability and utilization of immunotherapy treatments.

## Future Outlook

The [Keytruda Market](https://www.marketresearchfuture.com/reports/keytruda-market-19207) is projected to grow at a 9.2% CAGR from 2025 to 2035, driven by increasing cancer prevalence, advancements in immunotherapy, and expanding healthcare access.

**New opportunities:**

- Development of personalized treatment plans leveraging genetic profiling
- Expansion of telehealth services for remote patient monitoring
- Strategic partnerships with local healthcare providers for distribution efficiency

By 2035, the market is expected to achieve substantial growth, solidifying its position in the region.

## Segment Insights

### By Cancer Type: Melanoma (Largest) vs. Lung Cancer (Fastest-Growing)

In the South America keytruda market, melanoma represents the largest segment, commanding a significant market share. This is largely due to the rising incidence of skin cancers, particularly in regions with high UV exposure. Lung cancer follows closely, characterized by increasing awareness and better diagnostic measures that contribute to its substantial presence in the market. Other cancer types like Hodgkin lymphoma, stomach cancer, and urothelial carcinoma also hold noticeable shares but do not compare with the leading segments. The growth trends in this segment are driven by factors such as improved healthcare infrastructure, increasing access to innovative treatments, and heightened public awareness regarding cancer. The rapid adoption of immunotherapy in treating lung cancer is making it the fastest-growing segment, while melanoma remains pivotal due to its established treatment protocols with Keytruda. As research continues, further advancements in precision medicine are expected to alter market dynamics significantly.

Melanoma: Dominant vs. Lung Cancer: Emerging

Melanoma is the dominant segment in the South America keytruda market, largely due to its established treatment landscape that has been supported by extensive clinical studies. The treatment protocols for melanoma have become more refined, allowing for better patient outcomes and broader acceptance among oncologists. On the other hand, lung cancer is viewed as an emerging segment, driven by the increasing recognition of the effectiveness of Keytruda as a viable treatment option. This segment is characterized by rapid innovation and is projected to experience substantial growth as new clinical evidence surfaces and treatments become more widely available. Both segments play crucial roles in shaping the landscape of cancer treatment in the region.

### By Distribution Channel: Hospital Pharmacies (Largest) vs. Specialty Pharmacies (Fastest-Growing)

Hospital pharmacies currently hold the largest share in the distribution channel segment, reflecting a well-established network within healthcare institutions. They provide a key avenue for healthcare professionals to access keytruda for their patients, benefiting from strong relationships with hospitals and clinics. In contrast, specialty pharmacies are gaining traction, characterized by their focus on niche medications and personalized care, allowing for tailored patient experiences. Growth trends in this segment are driven by increasing adoption rates of keytruda among oncologists and healthcare providers. Enhanced patient education and awareness about treatment options are propelling specialty pharmacies to a more prominent role in the distribution channel. Furthermore, the shift towards value-based care and the emphasis on patient-centered services are likely to benefit specialty pharmacies, enhancing their market share in the coming years.

Hospital Pharmacies: Dominant vs. Specialty Pharmacies: Emerging

Hospital pharmacies play a dominant role in distributing keytruda, leveraging their established infrastructure and relationships to ensure accessibility for patients within healthcare systems. Their significant presence in hospitals allows for efficient medication management and direct patient care. Conversely, specialty pharmacies are emerging as pivotal players due to their tailored approach, offering intricate management of complex therapies like keytruda. They provide critical patient support services and better handle the insurance processes involved, making them increasingly preferred among patients requiring specialized treatment, thus reflecting a significant shift towards patient-centric options in today's healthcare landscape.

## Regional Market Share Analysis

### Brazil : Brazil's Expanding Oncology Landscape

Brazil holds a commanding market share of 42.1% in the South American Keytruda market, valued at $650.0 million. Key growth drivers include increasing cancer prevalence, enhanced healthcare access, and government initiatives promoting innovative therapies. Regulatory support from ANVISA has streamlined drug approvals, while investments in healthcare infrastructure bolster distribution channels. The rising demand for immunotherapy reflects changing consumption patterns among healthcare providers and patients alike.

### Mexico : Mexico's Growing Healthcare Investments

Mexico accounts for 18.8% of the South American Keytruda market, with a value of $300.0 million. The market is driven by increasing awareness of cancer treatments and government initiatives aimed at improving healthcare access. Regulatory frameworks are evolving, with COFEPRIS enhancing approval processes for innovative therapies. The demand for Keytruda is rising, particularly in urban areas, reflecting a shift towards advanced cancer treatments.

### Argentina : Argentina's Evolving Oncology Sector

Argentina represents 16.3% of the South American Keytruda market, valued at $250.0 million. Key growth factors include rising cancer incidence and a focus on improving healthcare quality. Government policies are increasingly supportive of innovative therapies, with ANMAT facilitating faster approvals. The demand for Keytruda is particularly strong in Buenos Aires and Córdoba, where healthcare infrastructure is more developed, fostering a competitive landscape among major players.

### Rest of South America : Diverse Opportunities in South America

The Rest of South America holds a market share of 9.5%, valued at $154.35 million. Growth is driven by increasing healthcare investments and a rising awareness of cancer treatments. Regulatory bodies in countries like Chile and Colombia are enhancing frameworks for drug approvals, creating a more favorable environment for Keytruda. Demand is growing in urban centers, but challenges remain in rural areas due to infrastructure limitations.

## Competitive Benchmarking

The competitive dynamics within the keytruda market exhibit a landscape characterized by rapid innovation and strategic maneuvering among key players. Major companies such as Merck & Co (US), Bristol-Myers Squibb (US), and Roche Holding AG (CH) are at the forefront, each leveraging distinct strategies to enhance their market presence. Merck & Co (US) continues to focus on expanding its clinical trial portfolio, particularly in immuno-oncology, which appears to be a pivotal area for growth. Meanwhile, Bristol-Myers Squibb (US) emphasizes strategic partnerships to bolster its research capabilities, particularly in combination therapies that enhance the efficacy of existing treatments. Roche Holding AG (CH) is investing heavily in digital health solutions, aiming to integrate data analytics into patient care, thereby enhancing treatment outcomes and operational efficiency.
The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure is moderately fragmented, with a few dominant players exerting considerable influence over pricing and innovation. This fragmentation allows for niche players to emerge, yet the collective strength of the major companies shapes the competitive environment significantly.
In October 2025, Merck & Co (US) announced a collaboration with a leading biotechnology firm to develop a novel combination therapy aimed at enhancing the effectiveness of keytruda in treating advanced melanoma. This strategic move underscores Merck's commitment to innovation and its proactive approach to addressing unmet medical needs in oncology. The partnership is expected to accelerate the development timeline and potentially expand the market share for keytruda in this therapeutic area.
In September 2025, Bristol-Myers Squibb (US) launched a new initiative focused on expanding access to immunotherapy treatments in underserved regions of South America. This initiative not only aligns with the company's corporate social responsibility goals but also positions it favorably in a competitive landscape increasingly focused on equitable healthcare access. By addressing barriers to treatment, Bristol-Myers Squibb (US) is likely to enhance its brand reputation and foster long-term loyalty among healthcare providers and patients alike.
In August 2025, Roche Holding AG (CH) unveiled a new digital platform designed to streamline patient data collection and enhance real-time monitoring of treatment responses. This platform is anticipated to facilitate more personalized treatment plans and improve patient outcomes, thereby reinforcing Roche's position as a leader in integrating technology with healthcare. The strategic importance of this initiative lies in its potential to differentiate Roche's offerings in a crowded market, where data-driven insights are becoming increasingly critical.
As of November 2025, the competitive landscape is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence (AI) into healthcare solutions. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient care. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements, innovative treatment modalities, and reliable supply chains. This shift suggests that companies that prioritize research and development, alongside sustainable practices, will be better positioned to thrive in the dynamic keytruda market.

## Recent News & Developments

In recent developments, the South America Keytruda Market has seen significant growth and interest from major pharmaceutical companies. Specifically, AbbVie and Bristol-Myers Squibb have been increasing their presence in the region, with AbbVie's acquisition of Allergan in May 2020 bolstering their oncology portfolio, which includes immunotherapies that compete with Keytruda. Merck & Co continues to lead the market, driven by the increasing adoption of Keytruda in various cancer treatments.

AstraZeneca has also been active, expanding its cancer pipeline with potential combinations that include immunotherapy options. In terms of recent market valuation growth, Merck & Co reported an increase in sales in the Latin America region, benefitting from rising healthcare expenditure and greater accessibility. Over the past few years, key events include the expansion of Keytruda’s indications in breast cancer treatment in Brazil in July 2021, further solidifying its presence in oncology. The consistent investments in healthcare infrastructure across South America, alongside rising cancer incidence rates, indicate a robust environment for Keytruda and its competitors moving forward.

## Report Scope

| MARKET SIZE 2024 | 1354.35(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1478.95(USD Million) |
| MARKET SIZE 2035 | 3566.65(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck & Co (US), Bristol-Myers Squibb (US), Roche Holding AG (CH), AstraZeneca PLC (GB), Novartis AG (CH), Pfizer Inc (US), Eli Lilly and Company (US), Amgen Inc (US) |
| Segments Covered | Cancer Type, Distribution Channel |
| Key Market Opportunities | Emerging immunotherapy advancements and regulatory support enhance growth potential in the keytruda market. |
| Key Market Dynamics | Rising demand for immunotherapy in South America drives competition and innovation in the Keytruda market. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What was the overall market valuation for the South America keytruda market in 2024?**
A: The overall market valuation was $1354.35 Million in 2024.

**Q: What is the projected market valuation for the South America keytruda market by 2035?**
A: The projected market valuation for 2035 is $3566.65 Million.

**Q: What is the expected CAGR for the South America keytruda market from 2025 to 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 9.2%.

**Q: Which cancer type had the highest market valuation in 2024?**
A: Lung cancer had the highest market valuation at $400.0 Million in 2024.

**Q: What is the market valuation range for stomach cancer in the South America keytruda market?**
A: The market valuation range for stomach cancer is between $250.0 Million and $700.0 Million.

**Q: Which distribution channel accounted for the largest market share in 2024?**
A: Hospital pharmacies accounted for the largest market share, with a valuation of $1087.5 Million.

**Q: What is the market valuation range for urothelial carcinoma in 2024?**
A: The market valuation range for urothelial carcinoma is between $354.35 Million and $866.65 Million.

**Q: Who are the key players in the South America keytruda market?**
A: Key players include Merck & Co, Bristol-Myers Squibb, Roche Holding AG, AstraZeneca PLC, Novartis AG, Pfizer Inc, Eli Lilly and Company, and Amgen Inc.

**Q: What is the market valuation range for Hodgkin lymphoma in 2024?**
A: The market valuation range for Hodgkin lymphoma is between $150.0 Million and $400.0 Million.

**Q: What is the market valuation range for specialty pharmacies in the South America keytruda market?**
A: The market valuation range for specialty pharmacies is between $266.85 Million and $726.65 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-keytruda-market-45327*